Schering-Plough completes buyout of Organon for more than $14 billion

KENILWORTH, N.J. Schering-Plough has completed its buyout of the biopharmaceutical company Organon BioSciences NV for about $14.43 billion in cash.

This is the completion of a deal first announced on March 12, and now expands Schering-Plough’s late-stage product pipeline and human health business. The deal provides Schering-Plough with five additional Phase III projects and furthers its reach into pharmaceutical franchises for women’s health and the central nervous system. The experimental products include an oral contraceptive, an asthma treatment and an HIV drug.

Schering-Plough’s prescription products will now include Organon’s fertility treatment Follistim, muscle relaxant Zemuron and vaginal contraceptive ring NuvaRing.